PO.MCB06.04 · 分子与细胞生物学
单细胞水平组蛋白修饰图谱分析以深入了解表观遗传药物治疗对肿瘤细胞的影响
Profiling histone modifications in single cells to gain insight into the effects of epigenetic drug treatment on tumor cells
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
表观基因组重塑(如染色质状态的变化)通过调控驱动肿瘤进展、免疫逃逸和治疗耐药演变的基因表达变化,在癌症生物学中发挥关键作用。研究表观基因组的常用方法包括转座酶可及染色质测序(ATAC-seq)和染色质免疫沉淀测序(ChIP-seq)。ATAC-seq仅分析开放染色质,遗漏了关于可及区域性质或沉默染色质的关键细节。ChIP-seq及其较新的同类方法——靶向切割与标记(CUT&Tag)——通过使用特异性抗体靶向组蛋白修饰,提供了关于染色质状态更为详细的信息。ChIP-seq需要10^6个细胞才能生成有意义的数据——对于珍贵样本而言过高。CUT&Tag以低10-100倍的输入量提供更高的灵敏度,并显著简化了工作流程。在研究癌症中的表观遗传变化时,鉴于肿瘤及其微环境的复杂性和异质性,单细胞分辨率被广泛认为是必不可少的。因此,将现有表观遗传检测从批量(bulk)转换为单细胞分辨率的需求很高。在CUT&Tag中,DNA由蛋白A/G-Tn5融合酶进行标记(tagment),该酶在原位插入测序接头以进行细胞特异性标记——从而实现单细胞分辨率。一些实验室已尝试单细胞CUT&Tag(scCUT&Tag),但在此我们提出一种新颖的、即用型、经过验证的自动化高通量scCUT&Tag方法。为评估药物诱导的乙酰化变化,我们在表观遗传治疗(地西他滨decitabine + 帕比司他panobinostat 与 DMSO对照)前后,对来自肺癌细胞系(A549 WT和A549 p53 KO)的数千个单细胞进行了H3K27ac模式图谱分析。我们在A549 WT和A549 p53 KO细胞中均观察到响应表观遗传治疗的全局细胞类型特异性乙酰化。将scCUT&Tag数据与单细胞总RNA-seq数据进行比较时,我们发现基因启动子和增强子处乙酰化的增加与基因表达的增加相关,印证了所观察到的组蛋白修饰变化。总之,经过验证的scCUT&Tag方法提供了一种高通量、自动化的方法,可在单细胞水平识别响应肿瘤细胞表观遗传药物治疗而受调控的基因。整合这一单细胞表达数据能更深入地了解细胞调控,尤其是在肿瘤细胞药物反应的背景下。
查看英文原文 English abstract
Epigenomic remodeling, such as changes in chromatin state, plays a crucial role in cancer biology by regulating gene expression changes that drive tumor progression, immune evasion, and the evolution of therapeutic resistance. Popular methods to study the epigenome include assay for transposase-accessible chromatin with sequencing (ATAC-seq) and chromatin immunoprecipitation sequencing (ChIP-seq). ATAC-seq only profiles open chromatin, missing critical details about the nature of accessible regions or silenced chromatin. ChIP-seq and its newer relative, cleavage under targets and tagmentation (CUT&Tag), provide more detailed information on chromatin states by targeting histone modifications with specific antibodies. ChIP-seq requires 10 6 cells to generate meaningful data-too high for precious samples. CUT&Tag offers higher sensitivity with 10-100x lower input and a significantly simplified workflow. When studying epigenetic changes in cancer, it is widely accepted that single-cell resolution is essential, given the complexity and heterogeneity of tumors and their microenvironment. Hence, there is a high demand to convert current epigenetic assays from bulk to single-cell resolution. In CUT&Tag, DNA is tagmented with a protein A/G-Tn5 fusion enzyme, which inserts sequencing adapters in situ for cell-specific labeling-enabling single-cell resolution. Some labs have experimented with single-cell CUT&Tag (scCUT&Tag), but here we present a novel, ready-to-use, validated method for automated, high-throughput scCUT&Tag. To assess drug induced changes in acetylation, we profiled H3K27ac patterns in thousands of single cells from a lung cancer cell line (A549 WT and A549 p53 KO) before and after epigenetic treatment (decitabine + panabinistat vs DMSO control).We observed global cell-type-specific acetylation in response to epigenetic therapy in both A549 WT and A549 p53 KO cells. When comparing scCUT&Tag data with single-cell total RNA-seq data we found that increased acetylation at gene promoters and enhancers correlated with increased gene expression, corroborating the observed changes in histone modification. In summary, the validated scCUT&Tag method provides a high-throughput, automated approach to identify genes regulated in response to epigenetic drug treatment of tumor cells at the single-cell level. Integrating this single-cell expression data provides deeper insight into cellular regulation, particularly in the context of drug responses in tumor cells.
利益披露 Disclosure
S. Chen, None..
L. Welter, None..
G. Sevilla, None..
P. Setthasap, None..
Y. Ryan, None..
S. Yin, None..
A. Du, None..
J. Peterson, None..
M. Covington, None..
M. Fallahi, None..
K. Tori, None..
B. Bell, None..
B. Graham, None..
M. J. Meiners, None..
A. L. Johnstone, None..
K. E. Maier, None..
M. W. Cowles, None..
B. J. Venters, None..
M. Keogh, None..
X. Qu, None..
C. McCornack, None..
T. Wang, None..
Y. Yun, None..
A. Farmer, None.